Wave Life Sciences (0VS) Stock Statistics & Valuation Metrics
Total Valuation
Wave Life Sciences has a market cap or net worth of EUR 633.99M. The enterprise value is EUR 368.14M.
- Market Cap
- EUR 633.99M
- Enterprise Value
- EUR 368.14M
Share Statistics
Wave Life Sciences has 197,228,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 197,228,970
- Owned by Insiders
- 28.50%
- Owned by Institutions
- 13.47%
Financial Efficiency
Wave Life Sciences’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -39.03%.
- Return on Equity (ROE)
- -0.39
- Return on Assets (ROA)
- -0.32
- Return on Invested Capital (ROIC)
- -39.03%
- Return on Capital Employed (ROCE)
- -0.40
- Revenue Per Employee
- 134.79K
- Profits Per Employee
- -644.73K
- Employee Count
- 317
- Asset Turnover
- 0.07
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Wave Life Sciences is -3.36. Wave Life Sciences’s PEG ratio is 0.06.
- PE Ratio
- -3.36
- PS Ratio
- 9.98
- PB Ratio
- 1.82
- Price to FCF
- -3.51
- Price to Operating Cash Flow
- -3.66
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, Wave Life Sciences had revenue of 42.73M and earned -204.38M in profits. Earnings per share was -1.21.
- Revenue
- 42.73M
- Gross Profit
- 33.88M
- Operating Income
- -215.38M
- Pretax Income
- -204.38M
- Net Income
- -204.38M
- EBITDA
- -195.53M
- Earnings Per Share (EPS)
- -1.21
Cash Flow
In the last 12 months, operating cash flow was -200.16M and capital expenditures -1.33M, giving a free cash flow of -201.48M billion.
- Operating Cash Flow
- -200.16M
- Free Cash Flow
- -201.48M
- Free Cash Flow per Share
- -0.99
Dividends & Yields
Wave Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -28.46%
- Earnings Yield
- -28.72%
Stock Price Statistics
- Beta
- 1.84
- 52-Week Price Change
- -56.10%
- 50-Day Moving Average
- 3.46
- 200-Day Moving Average
- 6.07
- Relative Strength Index (RSI)
- 50.62
- Average Volume (3m)
- 520
Important Dates
Wave Life Sciences upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Wave Life Sciences as a current ratio of 6.47, with Debt / Equity ratio of 3.38%
- Current Ratio
- 6.47
- Quick Ratio
- 6.47
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.99
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Wave Life Sciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Wave Life Sciences EV to EBITDA ratio is -2.70, with an EV/FCF ratio of -2.75.
- EV to Sales
- 7.81
- EV to EBITDA
- -2.70
- EV to Free Cash Flow
- -2.75
- EV to Operating Cash Flow
- -2.77
Balance Sheet
Wave Life Sciences has EUR 430.75M in cash and marketable securities with EUR 43.27M in debt, giving a net cash position of EUR 387.48M billion.
- Cash & Marketable Securities
- EUR 430.75M
- Total Debt
- EUR 43.27M
- Net Cash
- EUR 387.48M
- Net Cash Per Share
- EUR 1.96
- Tangible Book Value Per Share
- EUR 1.97
Margins
Gross margin is 96.81%, with operating margin of -320.94%, and net profit margin of -296.86%.
- Gross Margin
- 96.81%
- Operating Margin
- -320.94%
- Pretax Margin
- -296.86%
- Net Profit Margin
- -296.86%
- EBITDA Margin
- -289.73%
- EBIT Margin
- -302.74%
Analyst Forecast
The average price target for Wave Life Sciences is EUR 16.97, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 16.97
- Price Target Upside
- 448.46% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 17
- Revenue Growth Forecast
- -39.95%
- EPS Growth Forecast
- -41.57%
Scores
- Smart Score
- 7
- AI Score
- ―
